GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (AMEX:IGC) » Definitions » Effective Interest Rate on Debt %

IGC Pharma (IGC Pharma) Effective Interest Rate on Debt % : 0.00% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is IGC Pharma Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. IGC Pharma's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $0.00 Mil. IGC Pharma's average total debt for the quarter that ended in Dec. 2023 was $0.40 Mil. Therefore, IGC Pharma's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 0.00%.


IGC Pharma Effective Interest Rate on Debt % Historical Data

The historical data trend for IGC Pharma's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Effective Interest Rate on Debt % Chart

IGC Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IGC Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IGC Pharma's Effective Interest Rate on Debt %

For the Biotechnology subindustry, IGC Pharma's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGC Pharma's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Effective Interest Rate on Debt % falls into.



IGC Pharma Effective Interest Rate on Debt % Calculation

IGC Pharma's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Mar. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Mar. 2022 )+Total Debt  (A: Mar. 2023 ))/ count )
=-1  *  0/( (0.608+0.481)/ 2 )
=-1  *  0/0.5445
=0.00 %

where

Total Debt  (A: Mar. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.485 + 0.123
=0.608

Total Debt  (A: Mar. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.348 + 0.133
=0.481

IGC Pharma's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  0/( (0.415+0.377)/ 2 )
=-1  *  0/0.396
=0.00 %

where

Total Debt  (Q: Sep. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.285 + 0.13
=0.415

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.253 + 0.124
=0.377

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


IGC Pharma  (AMEX:IGC) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


IGC Pharma Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


IGC Pharma (IGC Pharma) Business Description

Industry
Traded in Other Exchanges
Address
10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Executives
James P Moran director 914 SPRING HILL ROAD, MCLEAN VA 22102
John Edward Lynch director 14 PARK AVENUE, REHOBOTH BEACH DE 19971
Richard K Prins director
Ram Mukunda director, officer: Exec. Chairman & CEO
Claudia Grimaldi officer: Vice president and PFO PO BOX 60642, POTOMAC MD 20859
Rohit Goel officer: Manager & PAO PO BOX 60642, POTOMAC MD 20859
John Cherin officer: CFO, Treasurer and PAO 662 LIVE OAK DRIVE, MCLEAN VA 22101
Shu Kwong Ngai director, officer: Interim CFO 4336 MONTGOMERY AVENUE, BETHESDA MD 20814
Ranga C Krishna director 330 THORNTON ROAD, ENGLEWOOD X1 07631
Sudhakar V Shenoy director 10411 MOTOR CITY DRIVE, BETHESDA MD 20817
Suhail Nathani director INDIA GLOBALIZATION CAPITAL, INC., 4336 MONTGOMERY AVE., BETHESDA MD 20814
Nisswa Acquisition Master Fund Ltd. 10 percent owner C/O MAPLES CORPORATE SVCS LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Smith Edward B Iii 10 percent owner C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
Ag Ubs 10 percent owner 600 WASHINGTON BLVD., STAMFORD CT 06901
Pine River Master Fund Ltd. 10 percent owner C/O PINE RIVER CAPITAL MANAGEMENT L.P., 601 CARLSON PARKWAY, 7TH FLOOR, MINNETONKA MN 55305

IGC Pharma (IGC Pharma) Headlines

From GuruFocus